Sign in
CompletedPhase 2

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Key facts

Who runs it
Knoa Pharma LLC
Where
Baytown, Brooklyn, Columbus, and Houston, United StatesSee the 4 sitesAlso in 1 other country, 3 sites
Status
Completed
Phase
Phase 2
People taking part
209 people enrolled
Started
14 Oct 2024
Ended
5 May 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Sunobinop
  • Placebo to match sunobinop
Record updated
5 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Male and female age ≥18 years
  • Diagnosis of moderate or severe alcohol use disorder
  • Currently seeking treatment for alcohol use disorder
  • Has 4 or more heavy drinking days (HDD) in each of the 4 weeks prior to baseline visit

Who cannot take part

  • Subjects that meet current DSM-5 criteria for moderate or severe substance use disorder other than alcohol and nicotine; Other protocol-specific inclusion and exclusion criteria may apply

Where in United States

Also in 1 other country, 3 sites

  • Inquest Clinical ResearchBaytown, United States
  • Belmont Medical OfficeBrooklyn, United States
  • Ohio Clinical TrialsColumbus, United States
  • Cebis Usa, LlcHouston, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.

The 2 groups in the trial

  • SunobinopTreatment being tested
  • Placebo to match sunobinopPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Consumption in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment
Record updated
5 June 2026